|
시장보고서
상품코드
2024207
유전자 발현 분석 시장 : 제공별, 용도별, 최종사용자별, 지역별 - 세계 예측(-2031년)Gene Expression Analysis Market by Product, Service, Application, End User, and Region - Global Forecast to 2031 |
||||||
유전자 발현 분석 시장 규모는 2026년 42억 3,000만 달러에서 2031년에는 59억 3,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR은 7.0%를 기록할 전망입니다.
이 시장은 트랜스스크립트믹스 기술 도입 확대와 정밀의료 및 맞춤치료에 대한 관심 증가에 힘입어 성장하고 있습니다. 차세대 시퀀싱, PCR, 마이크로어레이 등의 기술을 통해 유전자 활성의 정확하고 높은 처리량 분석이 가능해져 질병 연구 및 진단의 진보를 뒷받침하고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준 연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 대상 단위 | 금액(10억 달러) |
| 부문 | 제공별, 용도별, 최종사용자별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
또한, 바이오마커 발굴 및 신약개발에 있어 유전자 발현 프로파일링의 활용 확대는 연구 효율성과 임상 성과 향상에 기여하고 있습니다. 그러나 높은 장비 비용, 복잡한 데이터 분석, 숙련된 전문가의 필요성 등은 여전히 시장 성장을 제약하는 요인으로 작용하고 있습니다.
"시약 및 소모품 부문은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다."
시약 및 소모품 부문은 연구 및 임상 워크플로우 전반에 걸쳐 키트, 효소, 프로브 및 기타 소모품이 반복적으로 대량으로 사용되기 때문에 유전자 발현 분석 시장에서 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이들 제품은 PCR, 차세대 시퀀싱, 마이크로어레이 분석 등의 기술에 필수적인 제품으로 안정적인 수요를 확보하고 있습니다. 유전체학 및 전사체학 연구의 증가와 더불어 진단 및 신약 개발 연구에서의 유전자 발현 프로파일링의 채택이 확대되면서 이 부문의 성장을 더욱 촉진하고 있습니다. 또한, 지속적인 제품 혁신과 정확한 결과를 보장하기 위한 신뢰할 수 있는 고품질 시약에 대한 요구도 이 부문의 성장에 기여하고 있습니다. 시약 및 소모품은 높은 가성비와 지속적인 구매 특성으로 인해 시약 및 소모품 시장의 주요 성장 요인으로 작용하고 있습니다.
"신약개발 부문이 시장에서 가장 큰 점유율을 차지하고 있습니다."
신약개발 부문은 신약 타겟 발굴 및 검증을 위한 유전자 발현 프로파일링의 광범위한 활용에 힘입어 유전자 발현 분석 시장에서 가장 큰 점유율을 차지하고 있습니다. 이러한 기술은 유전자 기능, 질병 경로 및 치료 반응을 이해하는 데 중요한 역할을 하며, 이를 통해 신약 개발 과정의 효율성을 향상시키고 있습니다. 제약 및 생명공학 기업들은 바이오마커 발굴, 독성 평가, 유효성 평가에 있어 유전자 발현 분석에 대한 의존도가 높아지고 있습니다. 정밀의료와 표적치료에 대한 관심이 높아지고, R&D 투자 증가와 함께 이 부문의 우위가 더욱 강화되고 있습니다.
"예측 기간 동안 미국은 가장 높은 CAGR로 성장할 것으로 예상됩니다."
미국은 주요 생명공학 및 제약 기업의 강력한 존재감, 첨단 연구 인프라, 유전체학 및 전사체학 연구에 대한 관심 증가로 인해 유전자 발현 분석 시장에서 가장 높은 CAGR로 성장할 것으로 예상됩니다. 종양학, 유전질환, 정밀의학 등의 분야에서 유전자 발현 프로파일링의 채택이 확대되면서 시장 성장을 견인하는 주요 요인으로 작용하고 있습니다. 차세대 시퀀싱, PCR, 마이크로어레이와 같은 기술은 연구 및 임상 응용 분야에서 널리 사용되고 있으며, 이는 수요를 더욱 증가시키고 있습니다. 또한, 지원적인 규제 프레임워크, 유전체 연구에 대한 막대한 자금 지원, 분석 기술의 지속적인 발전이 시장 확대에 기여하고 있습니다.
Thermo Fisher Scientific Inc.(미국),Illumina, Inc.(미국),Bio-Rad Laboratories, Inc.(미국),QIAGEN(네덜란드),F. Hoffmann-La Roche Ltd.(미국), PacBio(미국), Agilent Technologies, Inc.(미국), Sysmex Corporation(일본), BGI(중국), Eurofins Scientific(룩셈부르크), Standard BioTools(미국), Oxford Nanopore Technologies plc(영국), GenScript(미국), Takara Bio Inc. Corporation(미국), Twist Bioscience(미국), Promega Corporation(미국), LGC Limited(영국), CD Genomics(미국), BioSpyder Technologies Inc. England Biolabs(미국)는 유전자 발현 분석 제품 및 서비스를 제공하는 주요 기업 중 일부입니다.
조사 범위
본 조사 보고서는 유전자 발현 분석 시장을 제공 품목(시약·소모품[어세이 키트, 효소, DNA 칩, 기타 시약·소모품], 장비[PCR, NGS, DNA 마이크로어레이, 기타 장비], 서비스[유전자 발현 분석 서비스{RNA 시퀀싱 서비스, 기타 서비스}, 바이오인포매틱스 솔루션]), 용도(신약 개발, 임상 진단, 기타 용도), 최종 사용자(제약·바이오기술 기업, 학술·연구 기관, 기타 최종 사용자), 및 지역(북미, 유럽, 아시아 태평양, 라틴 아메리카, 중동·아프리카)에 따라 분류하고 있습니다.
이 보고서의 범위에는 유전자 발현 분석 시장의 성장에 영향을 미치는 주요 요인(촉진요인, 억제요인, 도전 과제 및 기회 포함)에 대한 자세한 정보가 포함되어 있습니다. 주요 업계 진출 기업에 대한 종합적인 분석을 통해 사업 개요, 제품 포트폴리오, 주요 전략, 신제품 출시, 인수합병, 유전자 발현 분석 시장과 관련된 최근 동향에 대한 인사이트를 제공합니다. 또한, 본 보고서에는 유전자 발현 분석 산업 생태계의 신생 스타트업 기업들의 경쟁 분석도 포함되어 있습니다.
본 보고서 구매의 주요 이점
이 보고서는 전체 시장과 그 하위 부문의 수익 추정치를 제공함으로써 시장 리더와 신규 진입자를 지원합니다. 또한, 이해관계자들이 경쟁 상황을 더 깊이 이해하고, 자신의 비즈니스를 효과적으로 포지셔닝하고, 적절한 시장 진입 전략을 수립할 수 있는 인사이트를 얻을 수 있도록 돕습니다. 이 보고서를 통해 이해관계자들은 시장 동향을 파악하고 주요 시장 촉진요인, 억제요인, 기회 및 과제에 대한 정보를 얻을 수 있습니다.
본 보고서에서는 다음과 같은 사항에 대한 인사이트를 제공합니다:
- 시장 성장에 영향을 미치는 주요 촉진요인(신약개발 및 신약개발에서의 유전자 발현 분석 활용 확대, 질병 연구에서의 활용 확대, 유전자 발현 기반 진단 및 예후 검사 도입 증가), 제약요인(높은 장비 비용, 데이터 분석 및 해석의 복잡성), 기회요인(단일세포 분석 기술 도입 확대, 임상 및 중개 연구에서의 유전자 발현 분석 확대), 과제(표준화 부족) 번역 연구에서의 유전자 발현 분석 확대), 도전과제(표준화 부족) 분석
- 제품 개발/혁신 : 유전자 발현 분석 시장의 신제품 출시 및 혁신에 대한 심층적인 인사이트를 제공합니다.
- 시장 개발 : 수익성 높은 시장에 대한 종합적인 정보 및 각 지역의 시장 분석
- 시장 다각화 : 유전자 발현 분석 시장의 신제품, 미개척 지역, 최근 동향 및 투자에 관한 종합적인 정보
- 경쟁사 분석 : 주요 기업 - Thermo Fisher Scientific Inc.(미국), Illumina, Inc.(미국), Bio-Rad Laboratories, Inc(미국), QIAGEN(네덜란드), F. Hoffmann-La Roche Ltd. Revvity(미국), PacBio(미국), Agilent Technologies, Inc.(미국), Sysmex Corporation(일본), BGI(중국), Eurofins Scientific(룩셈부르크), Standard BioTools(미국), Oxford Nanopore Technologies plc(영국), GenScript(미국), Takara Bio Inc.(일본) 등 유전자 발현 분석 시장의 주요 기업 소개
자주 묻는 질문
목차
제1장 소개
제2장 주요 요약
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI에 의한 영향, 특허, 혁신, 그리고 향후 응용
제7장 규제 상황과 지속가능성에 대한 대처
제8장 고객 상황과 구매 행동
제9장 유전자 발현 분석 시장(제공별)
제10장 유전자 발현 분석 시장(용도별)
제11장 유전자 발현 분석 시장(최종사용자별)
제12장 유전자 발현 분석 시장(지역별)
제13장 경쟁 구도
제14장 기업 개요
제15장 조사 방법
제16장 부록
KSM 26.05.19The gene expression analysis market is expected to reach USD 5.93 billion in 2031 from USD 4.23 billion in 2026, at a CAGR of 7.0% during the forecast period. The market is driven by the increasing adoption of transcriptomics technologies and the growing focus on precision medicine and personalized therapeutics. Techniques such as next-generation sequencing, PCR, and microarrays enable accurate and high-throughput analysis of gene activity, supporting advancements in disease research and diagnostics.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Offering, Application, End User |
| Regions covered | North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa |
Furthermore, the rising use of gene expression profiling in biomarker discovery and drug development enhances research efficiency and clinical outcomes. However, high instrument costs, complex data analysis, and the need for skilled professionals continue to limit market growth.
"The reagents & consumables segment is expected to grow at the highest CAGR during the forecast period."
The reagents & consumables segment is projected to grow at the highest CAGR in the gene expression analysis market due to the repeated and high-volume usage of kits, enzymes, probes, and other consumables across research and clinical workflows. These products are essential for techniques such as PCR, next-generation sequencing, and microarray analysis, ensuring consistent demand. The increasing number of genomics and transcriptomics studies, along with the rising adoption of gene expression profiling in diagnostics and drug research, is further driving segment growth. Additionally, continuous product innovations and the need for reliable and high-quality reagents to ensure accurate results contribute to the expansion of this segment. Their cost-effectiveness and recurring purchase nature make reagents & consumables a key growth driver in the market.
"Drug discovery & development segment holds the largest share of the market."
The drug discovery & development segment accounts for the largest share of the gene expression analysis market, driven by the extensive use of gene expression profiling in identifying and validating drug targets. These technologies play a critical role in understanding gene function, disease pathways, and therapeutic responses, thereby improving the efficiency of drug development processes. Pharmaceutical and biotechnology companies increasingly rely on gene expression analysis for biomarker discovery, toxicity assessment, and efficacy evaluation. The growing focus on precision medicine and targeted therapies, along with rising R&D investments, further supports the dominance of this segment.
"The US is projected to grow at the highest CAGR during the forecast period."
The US is projected to grow at the highest CAGR in the gene expression analysis market due to its strong presence of leading biotechnology and pharmaceutical companies, advanced research infrastructure, and increasing focus on genomics and transcriptomics studies. Rising adoption of gene expression profiling in areas such as oncology, genetic disorders, and precision medicine is a key factor driving market growth. Technologies including next-generation sequencing, PCR, and microarrays are widely used across research and clinical applications, further boosting demand. Additionally, supportive regulatory frameworks, high funding for genomic research, and continuous advancements in analytical technologies contribute to market expansion.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side - 30%
- By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%
Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), PacBio (US), Agilent Technologies, Inc. (US), Sysmex Corporation (Japan), BGI (China), Eurofins Scientific (Luxembourg), Standard BioTools (US), Oxford Nanopore Technologies plc (UK), GenScript (US), Takara Bio Inc. (Japan), Danaher Corporation (US), Bruker (US), 10X Genomics (US), Zymo Research Corporation (US), Twist Bioscience (US), Promega Corporation (US), LGC Limited (UK), CD Genomics (US), BioSpyder Technologies Inc. (US), and New England Biolabs (US) are some of the key companies offering gene expression analysis products & services.
Research Coverage
This research report categorizes the gene expression analysis market by offering (reagents & consumables[assays & kits, enzymes, DNA chips, other reagents & consumables], instruments [PCR, NGS, DNA microarray, other instruments], services [gene expression analysis services{RNA sequencing services, other services}, bioinformatics solutions]), application (drug discovery & development, clinical diagnostics, other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).
The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the gene expression analysis market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the gene expression analysis market. This report also includes a competitive analysis of emerging startups in the gene expression analysis industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (growing use of gene expression analysis in drug discovery and development, expanding applications in disease research, and rising adoption of gene expression-based diagnostics and prognostics tests), restraints (High cost of instruments and complexity of data analysis and interpretation), opportunities (growing adoption of single-cell analysis technologies and expansion of gene expression analysis in clinical and translational research), and challenges (lack of standardization) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the gene expression analysis market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene expression analysis market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players, Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), PacBio (US), Agilent Technologies, Inc. (US), Sysmex Corporation (Japan), BGI (China), Eurofins Scientific (Luxembourg), Standard BioTools (US), Oxford Nanopore Technologies plc (UK), GenScript (US), Takara Bio Inc. (Japan), among others, for the gene expression analysis market
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN GENE EXPRESSION ANALYSIS MARKET
- 2.4 HIGH-GROWTH SEGMENTS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 GENE EXPRESSION ANALYSIS MARKET OVERVIEW
- 3.2 NORTH AMERICA: GENE EXPRESSION ANALYSIS MARKET, BY OFFERING
- 3.3 GENE EXPRESSION ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 3.4 GENE EXPRESSION ANALYSIS MARKET SHARE, BY OFFERING, 2026 VS 2031 (%)
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Growing use of gene expression analysis in drug discovery and development
- 4.2.1.2 Expanding applications in disease research
- 4.2.1.3 Rising adoption of gene expression-based diagnostics and prognostics tests
- 4.2.2 RESTRAINTS
- 4.2.2.1 High cost of instruments
- 4.2.2.2 Complexity of data analysis and interpretation
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Growing adoption of single-cell analysis technologies
- 4.2.3.2 Expansion of gene expression analysis in clinical and translational research
- 4.2.4 CHALLENGES
- 4.2.4.1 Lack of standardization
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 BARGAINING POWER OF BUYERS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 THREAT OF NEW ENTRANTS
- 5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
- 5.2.4 R&D TRENDS IN GLOBAL BIOTECH INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.4 ECOSYSTEM ANALYSIS
- 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
- 5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025 (USD)
- 5.5.1.1 Instruments
- 5.5.1.2 Consumables
- 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
- 5.5.2.1 Instruments
- 5.5.2.2 Consumables
- 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025 (USD)
- 5.6 TRADE ANALYSIS
- 5.6.1 IMPORT SCENARIO (HS CODE 3822.00)
- 5.6.2 EXPORT SCENARIO (HS CODE 3822.00)
- 5.6.3 IMPORT SCENARIO (HS CODE 9027.00)
- 5.6.4 EXPORT SCENARIO (HS CODE 9027.00)
- 5.7 KEY CONFERENCES & EVENTS, 2026-2027
- 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.9 INVESTMENT & FUNDING SCENARIO
- 5.10 CASE STUDY ANALYSIS
- 5.10.1 RNA SEQUENCING ENABLES CLINICAL DIAGNOSTIC ADVANCEMENTS IN RARE GENETIC DISORDERS
- 5.10.2 TRANSCRIPTOMIC PROFILING IMPROVES BIOMARKER DETECTION IN ONCOLOGY
- 5.10.3 GENE EXPRESSION ANALYSIS ENABLES FUNCTIONAL INTERPRETATION IN RARE DISEASE DIAGNOSTICS
- 5.11 IMPACT OF US TARIFFS-GENE EXPRESSION ANALYSIS MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON COUNTRIES/REGIONS
- 5.11.4.1 US
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END-USE INDUSTRIES
- 5.11.5.1 Pharmaceutical & biotechnology companies
- 5.11.5.2 CROs and academic & research institutes
- 5.11.5.3 Clinical laboratories
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 INTRODUCTION
- 6.2 KEY TECHNOLOGIES
- 6.2.1 QUANTITATIVE PCR (QPCR)
- 6.2.2 MICROARRAY TECHNOLOGY
- 6.2.3 RNA SEQUENCING
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 SINGLE-CELL ANALYSIS
- 6.3.2 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
- 6.3.3 SPATIAL BIOLOGY
- 6.4 TECHNOLOGY ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 METHODOLOGY
- 6.5.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
- 6.5.3 LIST OF KEY PATENTS
- 6.6 FUTURE APPLICATIONS
- 6.7 IMPACT OF AI/GEN AI ON GENE EXPRESSION ANALYSIS MARKET
- 6.7.1 TOP USE CASES AND MARKET POTENTIAL
- 6.7.2 BEST PRACTICES IN AI-ENABLED GENE EXPRESSION WORKFLOWS
- 6.7.3 CASE STUDIES RELATED TO AI IMPLEMENTATION IN GENE EXPRESSION ANALYSIS MARKET
- 6.7.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
- 6.7.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED GENERATIVE MOLECULAR DESIGN IN GENE EXPRESSION ANALYSIS MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Rest of the world
- 7.1.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9 GENE EXPRESSION ANALYSIS MARKET, BY OFFERING
- 9.1 INTRODUCTION
- 9.2 REAGENTS & CONSUMABLES
- 9.2.1 ASSAYS & KITS
- 9.2.1.1 Rising adoption of multi-omics and single-cell assay kits to drive market
- 9.2.1.2 RNA isolation kits
- 9.2.1.2.1 Increasing demand for high-quality RNA and integrated multi-omics workflows to drive market
- 9.2.1.3 cDNA synthesis kits
- 9.2.1.3.1 Growing demand for high-fidelity reverse transcription in advanced transcriptomics to drive market
- 9.2.1.4 Library preparation kits
- 9.2.1.4.1 Increasing adoption of high-throughput sequencing and multiomics workflows to drive market
- 9.2.1.5 PCR assays & kits
- 9.2.1.5.1 Expanding use of PCR-integrated workflows in diagnostics and precision medicine to drive market
- 9.2.1.6 Other assays & kits
- 9.2.2 ENZYMES
- 9.2.2.1 Advancements in high-fidelity, application-specific enzymes to drive market
- 9.2.3 DNA CHIPS
- 9.2.3.1 Increasing adoption of high-throughput DNA chips in large-scale genomics research to propel market
- 9.2.4 OTHER REAGENTS & CONSUMABLES
- 9.2.1 ASSAYS & KITS
- 9.3 INSTRUMENTS
- 9.3.1 PCR INSTRUMENTS
- 9.3.1.1 Increasing adoption of high-precision and automated PCR technologies to boost demand
- 9.3.2 NGS INSTRUMENTS
- 9.3.2.1 Expanding adoption of high-throughput NGS platforms to drive market
- 9.3.3 DNA MICROARRAY SCANNERS
- 9.3.3.1 Enhanced microarray performance and throughput to propel market
- 9.3.4 OTHER INSTRUMENTS
- 9.3.1 PCR INSTRUMENTS
- 9.4 SOFTWARE & SERVICES
- 9.4.1 GENE EXPRESSION ANALYSIS SERVICES
- 9.4.1.1 RNA sequencing services
- 9.4.1.1.1 Expanding transcriptomics research to propel market
- 9.4.1.2 Microarray analysis services
- 9.4.1.2.1 Increasing demand for standardized, high-throughput gene expression profiling in large-sample studies to propel market
- 9.4.1.3 qPCR profiling services
- 9.4.1.3.1 Increasing demand for precise gene expression quantification to propel market
- 9.4.1.4 Other gene expression analysis services
- 9.4.1.1 RNA sequencing services
- 9.4.2 BIOINFORMATICS SOLUTIONS
- 9.4.2.1 Rising demand for AI-driven bioinformatics solutions to support market growth
- 9.4.2.2 Bioinformatics & data analysis services
- 9.4.2.2.1 Rising complexity of multi-omics data and demand for AI-driven biological insights to drive market
- 9.4.2.3 Software
- 9.4.2.3.1 Gene expression databases
- 9.4.2.3.1.1 Increasing need for structured data management to drive market
- 9.4.2.3.2 Data analysis software & visualization tools
- 9.4.2.3.2.1 Increasing demand for simplified data analysis and effective visualization of complex gene expression datasets to drive market
- 9.4.2.3.3 Cloud-based analysis platforms
- 9.4.2.3.3.1 Increasing shift toward AI-enabled SaaS cloud ecosystems to drive market
- 9.4.2.3.1 Gene expression databases
- 9.4.1 GENE EXPRESSION ANALYSIS SERVICES
10 GENE EXPRESSION ANALYSIS MARKET, BY APPLICATION
- 10.1 INTRODUCTION
- 10.2 DRUG DISCOVERY & DEVELOPMENT
- 10.2.1 INCREASING AI-INTEGRATED TRANSCRIPTOMICS AND PRECISION MEDICINE TO PROPEL MARKET
- 10.3 CLINICAL DIAGNOSTICS
- 10.3.1 INTEGRATION OF AI-DRIVEN ANALYSIS AND ADVANCED MOLECULAR DIAGNOSTICS TO DRIVE MARKET
- 10.4 BASIC RESEARCH & FUNCTIONAL PATHWAY ANALYSIS
- 10.4.1 EXPANDING MULTI-OMICS RESEARCH AND AI-ENABLED BIOINFORMATICS PLATFORMS TO DRIVE MARKET
- 10.5 OTHER APPLICATIONS
11 GENE EXPRESSION ANALYSIS MARKET, BY END USER
- 11.1 INTRODUCTION
- 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 11.2.1 STRATEGIC PHARMA-TECH COLLABORATIONS TO DRIVE MARKET
- 11.3 ACADEMIC & RESEARCH INSTITUTES
- 11.3.1 EXPANSION OF OPEN-ACCESS GENOMIC RESOURCES TO PROPEL MARKET
- 11.4 HOSPITALS & CLINICAL LABORATORIES
- 11.4.1 INTEGRATION OF PRECISION ONCOLOGY TO PROPEL MARKET
- 11.5 CONTRACT RESEARCH ORGANIZATIONS (CROS)
- 11.5.1 INCREASING OUTSOURCING OF COMPLEX GENOMIC RESEARCH AND CLINICAL TRIALS TO PROPEL MARKET
- 11.6 OTHER END USERS
12 GENE EXPRESSION ANALYSIS MARKET, BY REGION
- 12.1 INTRODUCTION
- 12.2 NORTH AMERICA
- 12.2.1 US
- 12.2.1.1 Rapid adoption of spatial transcriptomics and advanced genomics platforms to drive market
- 12.2.2 CANADA
- 12.2.2.1 Increasing incidence of chronic diseases to drive market
- 12.2.1 US
- 12.3 EUROPE
- 12.3.1 GERMANY
- 12.3.1.1 Expanding genomics infrastructure and advanced bioinformatics platforms to drive market
- 12.3.2 UK
- 12.3.2.1 National genomics initiatives and large-scale multiomics research to drive market
- 12.3.3 FRANCE
- 12.3.3.1 Increasing R&D in life sciences research to fuel market
- 12.3.4 ITALY
- 12.3.4.1 Expanding precision medicine research and adoption of advanced sequencing technologies to support market growth
- 12.3.5 SPAIN
- 12.3.5.1 Large-scale genomics programs to boost demand
- 12.3.6 REST OF EUROPE
- 12.3.1 GERMANY
- 12.4 ASIA PACIFIC
- 12.4.1 CHINA
- 12.4.1.1 Large-scale genomics program to boost demand
- 12.4.2 JAPAN
- 12.4.2.1 Integration of AI-driven genomics and precision oncology to propel market
- 12.4.3 INDIA
- 12.4.3.1 Expansion of national genomic databases to drive market
- 12.4.4 AUSTRALIA
- 12.4.4.1 National genomics integration to drive market
- 12.4.5 SOUTH KOREA
- 12.4.5.1 Government-led genomic data initiatives to boost demand
- 12.4.6 REST OF ASIA PACIFIC
- 12.4.1 CHINA
- 12.5 LATIN AMERICA
- 12.5.1 BRAZIL
- 12.5.1.1 Growth in the biopharmaceutical industry to support market
- 12.5.2 MEXICO
- 12.5.2.1 Increasing incidence of diabetes and growing geriatric population to propel market
- 12.5.3 REST OF LATIN AMERICA
- 12.5.1 BRAZIL
- 12.6 MIDDLE EAST
- 12.6.1 GCC COUNTRIES
- 12.6.1.1 Saudi Arabia
- 12.6.1.1.1 National genomics strategies and precision medicine integration to support market growth
- 12.6.1.2 United Arab Emirates
- 12.6.1.2.1 NGS-driven collaborations to fuel market
- 12.6.1.3 Rest of GCC Countries
- 12.6.1.1 Saudi Arabia
- 12.6.2 REST OF MIDDLE EAST
- 12.6.1 GCC COUNTRIES
- 12.7 AFRICA
- 12.7.1 EXPANDING GENOMICS RESEARCH CAPACITY AND DISEASE-FOCUSED INITIATIVES TO SUPPORT MARKET GROWTH
13 COMPETITIVE LANDSCAPE
- 13.1 INTRODUCTION
- 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE EXPRESSION ANALYSIS MARKET, JANUARY 2023-MARCH 2026
- 13.3 REVENUE ANALYSIS, 2021-2025
- 13.4 MARKET SHARE ANALYSIS, 2025
- 13.5 BRAND COMPARISON
- 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 13.6.1 STARS
- 13.6.2 EMERGING LEADERS
- 13.6.3 PERVASIVE PLAYERS
- 13.6.4 PARTICIPANTS
- 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 13.6.5.1 Company footprint
- 13.6.5.2 Region footprint
- 13.6.5.3 Offering footprint
- 13.6.5.4 Application footprint
- 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 13.7.1 PROGRESSIVE COMPANIES
- 13.7.2 RESPONSIVE COMPANIES
- 13.7.3 DYNAMIC COMPANIES
- 13.7.4 STARTING BLOCKS
- 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 13.7.5.1 Detailed list of key startups/SMEs
- 13.7.5.2 Competitive benchmarking of key startups/SMEs
- 13.8 COMPANY VALUATION & FINANCIAL METRICS
- 13.8.1 COMPANY VALUATION
- 13.8.2 FINANCIAL METRICS
- 13.9 COMPETITIVE SCENARIO
- 13.9.1 PRODUCT LAUNCHES
- 13.9.2 DEALS
- 13.9.3 EXPANSIONS
14 COMPANY PROFILES
- 14.1 KEY PLAYERS
- 14.1.1 THERMO FISHER SCIENTIFIC INC.
- 14.1.1.1 Business overview
- 14.1.1.2 Products/Services offered
- 14.1.1.3 Recent developments
- 14.1.1.3.1 Product launches
- 14.1.1.3.2 Deals
- 14.1.1.3.3 Expansions
- 14.1.1.4 MnM view
- 14.1.1.4.1 Key strengths
- 14.1.1.4.2 Strategic choices
- 14.1.1.4.3 Weaknesses and competitive threats
- 14.1.2 BIO-RAD LABORATORIES, INC.
- 14.1.2.1 Business overview
- 14.1.2.2 Products/Services offered
- 14.1.2.3 Recent developments
- 14.1.2.3.1 Product launches
- 14.1.2.3.2 Deals
- 14.1.2.4 MnM view
- 14.1.2.4.1 Key strengths
- 14.1.2.4.2 Strategic choices
- 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 ILLUMINA, INC.
- 14.1.3.1 Business overview
- 14.1.3.2 Products/Services offered
- 14.1.3.3 Recent developments
- 14.1.3.3.1 Product launches
- 14.1.3.3.2 Deals
- 14.1.3.4 MnM view
- 14.1.3.4.1 Key strengths
- 14.1.3.4.2 Strategic choices
- 14.1.3.4.3 Weaknesses and competitive threats
- 14.1.4 QIAGEN
- 14.1.4.1 Business overview
- 14.1.4.2 Products/Services offered
- 14.1.4.3 Recent developments
- 14.1.4.3.1 Product launches
- 14.1.4.3.2 Deals
- 14.1.4.4 MnM view
- 14.1.4.4.1 Key strengths
- 14.1.4.4.2 Strategic choices
- 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 REVVITY
- 14.1.5.1 Business overview
- 14.1.5.2 Products/Services offered
- 14.1.5.3 Recent developments
- 14.1.5.3.1 Deals
- 14.1.5.3.2 Expansions
- 14.1.5.4 MnM view
- 14.1.5.4.1 Key strengths
- 14.1.5.4.2 Strategic choices
- 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 F. HOFFMANN-LA ROCHE LTD.
- 14.1.6.1 Business overview
- 14.1.6.2 Products/Services offered
- 14.1.6.3 Recent developments
- 14.1.6.3.1 Product launches
- 14.1.6.3.2 Deals
- 14.1.6.3.3 Other developments
- 14.1.7 PACBIO
- 14.1.7.1 Business overview
- 14.1.7.2 Products/Services offered
- 14.1.7.3 Recent developments
- 14.1.7.3.1 Product launches
- 14.1.7.3.2 Deals
- 14.1.7.3.3 Expansions
- 14.1.8 AGILENT TECHNOLOGIES, INC.
- 14.1.8.1 Business overview
- 14.1.8.2 Products/Services offered
- 14.1.9 SYSMEX CORPORATION
- 14.1.9.1 Business overview
- 14.1.9.2 Products/Services offered
- 14.1.9.3 Recent developments
- 14.1.9.3.1 Deals
- 14.1.9.3.2 Other developments
- 14.1.10 BGI
- 14.1.10.1 Business overview
- 14.1.10.2 Products/Services offered
- 14.1.11 EUROFINS SCIENTIFIC
- 14.1.11.1 Business overview
- 14.1.11.2 Products/Services offered
- 14.1.12 STANDARD BIOTOOLS
- 14.1.12.1 Business overview
- 14.1.12.2 Products/Services offered
- 14.1.12.3 Recent developments
- 14.1.12.3.1 Product launches
- 14.1.13 OXFORD NANOPORE TECHNOLOGIES PLC
- 14.1.13.1 Business overview
- 14.1.13.2 Products/Services offered
- 14.1.13.3 Recent developments
- 14.1.13.3.1 Deals
- 14.1.13.3.2 Expansions
- 14.1.14 GENSCRIPT
- 14.1.14.1 Business overview
- 14.1.14.2 Products/Services offered
- 14.1.14.3 Recent developments
- 14.1.14.3.1 Deals
- 14.1.14.3.2 Expansions
- 14.1.15 TAKARA BIO INC.
- 14.1.15.1 Business overview
- 14.1.15.2 Products/Services offered
- 14.1.15.3 Recent developments
- 14.1.15.3.1 Product launches
- 14.1.15.3.2 Deals
- 14.1.16 DANAHER CORPORATION
- 14.1.16.1 Business overview
- 14.1.16.2 Products/Services offered
- 14.1.16.3 Recent developments
- 14.1.16.3.1 Deals
- 14.1.17 BRUKER
- 14.1.17.1 Business overview
- 14.1.17.2 Products/Services offered
- 14.1.17.3 Recent developments
- 14.1.17.3.1 Deals
- 14.1.1 THERMO FISHER SCIENTIFIC INC.
- 14.2 OTHER PLAYERS
- 14.2.1 10X GENOMICS
- 14.2.2 ZYMO RESEARCH CORPORATION
- 14.2.3 TWIST BIOSCIENCE
- 14.2.4 PROMEGA CORPORATION
- 14.2.5 LGC LIMITED
- 14.2.6 CD GENOMICS
- 14.2.7 BIOSPYDER TECHNOLOGIES INC.
- 14.2.8 NEW ENGLAND BIOLABS
15 RESEARCH METHODOLOGY
- 15.1 RESEARCH DATA
- 15.1.1 SECONDARY DATA
- 15.1.1.1 Key data from secondary sources
- 15.1.2 PRIMARY DATA
- 15.1.2.1 Key data from primary sources
- 15.1.2.2 Key primary participants
- 15.1.2.3 Breakdown of primary interviews
- 15.1.2.4 Key industry insights
- 15.1.1 SECONDARY DATA
- 15.2 MARKET SIZE ESTIMATION
- 15.2.1 GLOBAL GENE EXPRESSION ANALYSIS MARKET ESTIMATION, 2025
- 15.2.2 SEGMENTAL MARKET SIZE ESTIMATION
- 15.3 MARKET GROWTH RATE PROJECTIONS
- 15.4 DATA TRIANGULATION
- 15.5 FACTOR ANALYSIS
- 15.6 RESEARCH ASSUMPTIONS
- 15.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT
16 APPENDIX
- 16.1 DISCUSSION GUIDE
- 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 16.3 CUSTOMIZATION OPTIONS
- 16.4 RELATED REPORTS
- 16.5 AUTHOR DETAILS
